ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

ClinicalTrials.gov ID: NCT02592876

Public ClinicalTrials.gov record NCT02592876. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant

Study identification

NCT ID
NCT02592876
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Seagen Inc.
Industry
Enrollment
81 participants

Conditions and interventions

Interventions

  • carboplatin Drug
  • denintuzumab mafodotin Drug
  • etoposide Drug
  • ifosfamide Drug
  • rituximab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2015
Primary completion
Apr 19, 2018
Completion
Apr 19, 2018
Last update posted
May 16, 2019

2015 – 2018

United States locations

U.S. sites
29
U.S. states
19
U.S. cities
27
Facility City State ZIP Site status
University of Arkansas for Medical Sciences Little Rock Arkansas 72205
City of Hope National Medical Center Duarte California 91010-3000
Scripps Mercy Cancer Center San Diego California 92103
Colorado Blood Cancer Institute Denver Colorado 80218
Yale Cancer Center New Haven Connecticut 06520
Shands Cancer Center / University of Florida Gainesville Florida 32610
University of Miami Miami Florida 33136
H. Lee Moffitt Cancer Center & Research Institute Tampa Florida 33612
Winship Cancer Institute / Emory University School of Medicine Atlanta Georgia 30322
Rush University Medical Center Chicago Illinois 60612
University of Chicago Chicago Illinois 60637-1470
Cardinal Bernardin Cancer Center / Loyola University Medical Center Maywood Illinois 60153
University of Kansas Cancer Center Westwood Kansas United States
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Dana Farber Cancer Institute Boston Massachusetts 02215
University of Minnesota Minneapolis Minnesota 55455
Washington University School of Medicine St Louis Missouri 63110
Hackensack University Medical Center Hackensack New Jersey 07601
University of New Mexico Cancer Center Albuquerque New Mexico 87106
Memorial Sloan Kettering Cancer Center New York New York 10021
UNC Lineberger Comprehensive Cancer Center / University of North Carolina Chapel Hill North Carolina 27599
Levine Cancer Institute Charlotte North Carolina 28204
Duke University Medical Center Durham North Carolina 27710
MD Anderson Cancer Center / University of Texas Houston Texas 77030-4095
San Antonio Military Medical Center San Antonio Texas 78234
University of Virginia Charlottesville Virginia 22908
Seattle Cancer Care Alliance / University of Washington Seattle Washington 98109-1023
Carbone Cancer Center / University of Wisconsin Madison Wisconsin United States
Medical College of Wisconsin (Milwaukee) Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02592876, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 16, 2019 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02592876 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →